PellePharm: BridgeBio Pharma : PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma

(marketscreener.com) PellePharm, Inc., a BridgeBio Pharma, Inc. company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma . HF-BCC is a rare disease that causes a higher than average number of BCCs to develop, specifically...https://www.marketscreener.com/BRIDGEBIO-PHARMA-INC-60342525/news/BridgeBio-Pharma-PellePharm-Initiates-Phase-2-Clinical-Trial-of-Patidegib-Topical-Gel-for-People-W-29807358/?utm_medium=RSS&utm_content=20200108